Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Operating Leases: 2022-2025

Historic Operating Leases for Xeris Biopharma Holdings (XERS) over the last 3 years, with Sep 2025 value amounting to $38.2 million.

  • Xeris Biopharma Holdings' Operating Leases fell 3.77% to $38.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year decrease of 3.77%. This contributed to the annual value of $33.3 million for FY2024, which is 4.33% down from last year.
  • Xeris Biopharma Holdings' Operating Leases amounted to $38.2 million in Q3 2025, which was down 1.07% from $38.6 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Operating Leases peaked at $39.7 million during Q3 2024, and registered a low of $9.4 million during Q4 2022.
  • Moreover, its 3-year median value for Operating Leases was $38.2 million (2025), whereas its average is $35.2 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Operating Leases surged by 269.75% in 2023, and later dropped by 4.33% in 2024.
  • Over the past 4 years, Xeris Biopharma Holdings' Operating Leases (Quarterly) stood at $9.4 million in 2022, then spiked by 269.75% to $34.8 million in 2023, then dropped by 4.33% to $33.3 million in 2024, then fell by 3.77% to $38.2 million in 2025.
  • Its Operating Leases was $38.2 million in Q3 2025, compared to $38.6 million in Q2 2025 and $39.0 million in Q1 2025.